Wonder drug for hepatitis C has $90,000 price tag
WASHINGTON — Your money or your life?
Sovaldi, a new pill for hepatitis C, cures the liver-wasting disease in 9 of 10 patients, but treatment can cost more than $90,000.
Leading medical societies recommend the drug as a first-line treatment, and patients are clamoring for it. But insurance companies and state Medicaid programs are balking at the price. In Oregon, officials propose to limit how many low-income patients can get Sovaldi.
Yet if Sovaldi didn't exist, insurers would still be paying in the mid-to-high five figures to treat the most common kind of hepatitis C, a new pricing survey indicates. Some of the older alternatives involve more side effects, and are less likely to provide cures.
So what's a fair price?
The cost of this breakthrough drug is highlighting cracks in the health care system at a time of heightened budget concerns. The Obama administration has a huge political stake in controlling treatment costs, but its critics may cry rationing.
“People are going to want to try to dodge this hot potato,” says economist Douglas Holtz-Eakin.
For insurers, there's a frustrating twist: For each middle-aged person they pay to cure with Sovaldi, any financial benefits from preventing liver failure are likely to accrue to Medicare, not to them.
More than 3 million Americans carry the hepatitis C virus, and many don't realize it. It's a public health concern since the disease can be transmitted by contact with infected blood, and sometimes through sexual activity. Health officials advise all baby boomers to get tested.
Show commenting policy
TribLive commenting policy
- House OKs bill to address border crisis
- Defense spending cuts a ‘strategic misstep,’ panel warns in Pentagon review
- Cantor to leave House early
- Sudanese Christians thankful for freedom
- 2-pound ‘Mighty Girl’ has tricky heart surgery
- Obama’s plan could keep millions of immigrants in U.S. illegally
- Bristol, Va., museum lauds ‘hillbilly’ music
- Stowaway’s access to Air Force plane eyed
- CIA chief’s job could be at risk over Senate probe
- Lobbyists required to wear badges at Utah Capitol
- Treatment, not trial, for girl, 12, held in stabbing